Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Cancer Therapies02:49

Cancer Therapies

9.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

530
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
530
Tumor Immunotherapy01:27

Tumor Immunotherapy

877
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
877
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Community state shifts driven by total carbon availability over resource complexity in a synthetic microbial community.

ISME communications·2026
Same author

Normative assembly rule reveals fairness in microbial communities.

PLoS biology·2026
Same author

Evolution induced state shifts in a long-term microbial community experiment.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

bioRxiv : the preprint server for biology·2026
Same author

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

HemaSphere·2026
Same author

Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data.

BioData mining·2026
Same journal

DeepMethylation: A deep learning framework for tissue-specific DNA methylation prediction and functional variant annotation.

PLoS computational biology·2026
Same journal

Redefining and estimating the early-phase reproduction ratio for epidemic outbreaks in spatially structured populations.

PLoS computational biology·2026
Same journal

Optimized phenotype definitions boost GWAS power.

PLoS computational biology·2026
Same journal

Detection, communication, and individual identification with deep audio embeddings: A case study with North Atlantic right whales.

PLoS computational biology·2026
Same journal

Exploring the structural lexicon of the Proteome via Metric Geometry.

PLoS computational biology·2026
Same journal

Linking retinal sampling in neural encoding models to temporal profiles of visual processing in humans.

PLoS computational biology·2026
See all related articles

Related Experiment Video

Updated: Nov 24, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K

Multiobjective optimization identifies cancer-selective combination therapies.

Otto I Pulkkinen1,2,3,4, Prson Gautam1, Ville Mustonen2,5

  • 1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Plos Computational Biology
|December 28, 2020
PubMed
Summary
This summary is machine-generated.

This study presents a new optimization method to find the best drug combinations for advanced cancers resistant to single treatments. The approach identifies effective and safe combination therapies tailored to individual patients, improving cancer cell targeting.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.2K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.4K

Related Experiment Videos

Last Updated: Nov 24, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.2K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.4K

Area of Science:

  • Oncology
  • Computational Biology
  • Pharmacology

Background:

  • Advanced cancers often develop resistance to single-drug therapies (monotherapies) by activating redundant signaling pathways.
  • Identifying effective drug combinations is challenging due to the vast number of possibilities and the need for patient-specific approaches.
  • Current methods often lack cost-effectiveness and systematic strategies for optimizing combinatorial treatments.

Purpose of the Study:

  • To develop an exact multiobjective optimization method for identifying safe and effective cancer-selective drug combinations.
  • To prioritize patient-specific combination therapies based on Pareto-optimization of therapeutic and nonselective effects.
  • To demonstrate the method's applicability in optimizing combinatorial treatments for BRAF-V600E melanoma.

Main Methods:

  • Developed an exact multiobjective optimization framework for combinatorial therapy selection.
  • Utilized Pareto-optimization to balance therapeutic efficacy and nonselective effects across drug combinations.
  • Applied the method to BRAF-V600E melanoma, predicting co-inhibition partners for vemurafenib.
  • Experimentally validated predicted drug combinations in BRAF-V600E melanoma cell lines.

Main Results:

  • The optimization method successfully predicted multiple effective co-inhibition partners for vemurafenib in BRAF-V600E melanoma.
  • Experimental validation confirmed that combinatorial targeting of MAPK/ERK and compensatory pathways enhances selective inhibition of cancer cells.
  • The approach demonstrated the potential of pairwise and third-order drug combinations to improve treatment outcomes.
  • The method proved effective without requiring specific target information or genomic profiles.

Conclusions:

  • The developed mechanism-agnostic optimization method offers a systematic and cost-effective approach to identify optimal combinatorial cancer therapies.
  • This data-driven strategy is broadly applicable across various cancer types, supporting functional precision oncology.
  • The findings suggest a paradigm shift towards optimizing patient-specific combination treatments beyond genetic dependency.
  • Combinatorial therapies targeting redundant and compensatory pathways show promise for overcoming drug resistance in advanced cancers.